CD33 and acute myeloid leukemia: On the other hand, a clinical trial of TriKE specific to CD33 (NCT03214666) for treatment of relapse/refractory AML reported completed therapy (5–150 μg/kg per day) without dose limiting toxicity [12], suggesting the advantage of TriKEs.